In part 1 of this interview, Cate Lockhart, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, details some of her expectations for further growth of the US biosimilar market.
The Center for Biosimilars® recently spoke with Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, about the infliximab market, the pipeline of biosimilar products on the horizon, and the need for more real world evidence.
In the interview, Lockhart talks about how infliximab biosimilars have seen tepid acceptance in the United States compared with other countries, achieving only 7% uptake despite being some of the first biosimilars on the US market.
Although she said it’s unclear what would change the game for infliximab biosimilars, she noted that other biosimilars have achieved higher usage, suggesting that more broader uptake overall will become the standard trend.
She also discussed the biosimilars pipeline that currently has more than 70 potential products. Lockhart said slow uptake for infliximab biosimilars might have discouraged some companies from pursuing biosimilars, but seeing how robust the pipeline currently is makes her hopeful that more candidates will receive FDA approval, especially as the COVID-19 pandemic continues to wind down in the United States.
Lockhart also explained how more real world evidence on use of biosimilars could help alleviate persuade more physicians to prescribe these products. She added that policy guidances can be ambiguous and that real world evidence can play an important role in informing decision makers.
Additionally, Lockhart said that real world evidence could provide payers an alternative evidence source to traditional clinical trials, enabling them to feel more comfortable with biosimilars and better inform their formulary decision making.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Real-World Study: No Increase in Health Resource Costs After Infliximab Biosimilar Introduction
July 20th 2024Although biosimilars reduce drug purchasing costs for hospitals, it’s unclear whether those savings might be offset by increased health resource utilization following a non-medical switching initiative.